Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-26-182036
Filing Date
2026-04-27
Accepted
2026-04-27 16:05:17
Documents
19
Period of Report
2026-06-09

Document Format Files

Seq Description Document Type Size
1 DEF 14A mcrb-20260427.htm   iXBRL DEF 14A 2183068
2 GRAPHIC img86546405_0.jpg GRAPHIC 190953
3 GRAPHIC img86546405_1.jpg GRAPHIC 65052
4 GRAPHIC img86546405_2.gif GRAPHIC 183406
5 GRAPHIC img86546405_3.gif GRAPHIC 188711
6 GRAPHIC img86546405_4.jpg GRAPHIC 65052
7 GRAPHIC img86546405_5.jpg GRAPHIC 318712
8 GRAPHIC img86546405_6.jpg GRAPHIC 387355
  Complete submission text file 0001193125-26-182036.txt   6834045

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT mcrb-20260427.xsd EX-101.SCH 21630
22 EXTRACTED XBRL INSTANCE DOCUMENT mcrb-20260427_htm.xml XML 259215
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

EIN.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37465 | Film No.: 26900843
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)